Icotrokinra, sold as Icotyde, is Johnson & Johnson's oral peptide for moderate-to-severe plaque psoriasis. The FDA approved it on March 18, 2026, based on four Phase 3 trials. At week 16, 65% of patients on the drug had clear or almost clear skin in ICONIC-LEAD and 57% in ICONIC-TOTAL, which enrolled people with psoriasis on hard-to-treat areas; in the two ICONIC-ADVANCE trials against the pill Sotyktu, the figures were 68% and 71%.
One-year data presented at AAD 2026 showed 49% complete clearance at week 52 (close to 60% in adolescents), with no new safety signals reported. The drug is one of the more visible recent oral peptide approvals outside the GLP-1 class, and an early test of whether oral peptides can compete in inflammatory disease. Our Icotyde guide compares it with shots and other pills.
On Monday September 21, 2026, Johnson & Johnson announced that the European Commission granted marketing authorization for ICOTYDE (icotrokinra) for adults and adolescents aged 12 and older weighing at least 40 kg with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. J&J calls icotrokinra the first targeted oral peptide that precisely blocks the IL-23 receptor. The approval rests on the ICONIC program of four Phase 3 studies in about 2,500 patients; in the head-to-head studies, about 70% of patients reached clear or almost clear skin and 55% reached PASI 90 at week 16. Patients take one pill once daily with water on waking, at least 30 minutes before eating. Icotrokinra was jointly discovered and is being developed under J&J's license and collaboration agreement with Protagonist Therapeutics (NASDAQ: PTGX).
Two-year results from the Phase 3 ICONIC-TOTAL trial, presented at the EADV Congress in Vienna on October 2, 2026, covered 311 people with psoriasis on the scalp, genitals, hands, or feet. Among patients on the drug, 70% had clear or almost clear skin at week 112, and 89% of those with genital psoriasis had complete clearance there.
Stories here cover trial readouts, AAD presentations, EU launch dynamics, and the broader J&J peptide pipeline. See #psoriasis, #dermatology, #protagonist-therapeutics, and #johnson-johnson.
Johnson & Johnson said on October 9, 2026, at the Fall Clinical Dermatology Conference, that in the Phase 3 ICONIC-LEAD trial of its oral IL-23 receptor-blocking peptide Icotyde (icotrokinra) in 684 people aged 12 and older with moderate to severe plaque psoriasis, at least 70% of treated patients had clear or almost clear skin, at least 44% had completely clear skin by PASI 100, and at least 72% reached PASI 90 at week 112. Among people who reached PASI 90, stopped the drug at week 24, and later restarted it, 85% regained that response within 24 weeks. The release does not say how patients who left the study were counted, and J&J reported no new safety signals.
Johnson & Johnson reported two-year results on Friday, October 2, 2026, at the EADV Congress in Vienna from the Phase 3 ICONIC-TOTAL trial of Icotyde (icotrokinra), a once-daily oral peptide that blocks the IL-23 receptor, in 311 people aged 12 and older with psoriasis on the scalp, genitals, hands, or feet (208 on icotrokinra and 103 on placebo, who switched to the drug at week 16). Among icotrokinra-treated patients, the share with clear or almost clear skin rose from 57% at week 16 to 70% at week 112, and 60% of those with scalp psoriasis, 89% with genital psoriasis, and 63% with hand or foot psoriasis had complete clearance at those sites. Missing data after week 52 were handled with multiple imputation, and J&J reported no new safety signals.
Johnson & Johnson announced on Monday, September 21, 2026 that the European Commission granted marketing authorization for ICOTYDE (icotrokinra) for adults and adolescents aged 12 and older weighing at least 40 kg with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. J&J calls icotrokinra the first targeted oral peptide that precisely blocks the IL-23 receptor; it was jointly discovered and is being developed under J&J's license and collaboration agreement with Protagonist Therapeutics. The approval rests on the ICONIC program of four Phase 3 studies in about 2,500 patients (ICONIC-LEAD, ICONIC-TOTAL, ICONIC-ADVANCE 1 and 2). In the head-to-head studies, about 70% of patients on icotrokinra reached clear or almost clear skin (IGA 0/1) and 55% reached PASI 90 at week 16. Patients take one pill once daily with water on waking, at least 30 minutes before eating.
Protagonist Therapeutics (NASDAQ: PTGX) disclosed Friday August 28, 2026 that the Mimrylo FDA approval triggers $275 million in payments from Takeda, consisting of a $200 million opt-out fee (representing Protagonist's decision not to co-commercialize) and a separate $75 million approval milestone. The company retains additional undisclosed milestones and tiered royalties on rusfertide sales under the January 2024 worldwide license and collaboration agreement. Protagonist's platform-derived pipeline extends beyond rusfertide to include icotrokinra (an oral IL-23 receptor antagonist peptide licensed to Janssen, with a broad autoimmune-disease Phase 3 program) plus additional preclinical peptide programs across metabolic, inflammatory, and hematologic indications. The company's stock is expected to be one of the notable peptide-focused public-market performers of 2026 as rusfertide commercial ramp and icotrokinra Phase 3 readouts advance.
Oral peptide icotrokinra delivered complete skin clearance through week 52 with a strong safety profile in the ICONIC-ADVANCE trials, presented at the American Academy of Dermatology meeting.
One-year Phase 3 data at AAD 2026 show ICOTYDE (icotrokinra) achieves 49% complete clearance at Week 52, with nearly 60% in adolescents. No new safety signals.
J&J's icotrokinra (Icotyde) approved for moderate-to-severe plaque psoriasis; in the two head-to-head trials against the pill deucravacitinib (Sotyktu), about 70% of patients achieved clear or almost clear skin by week 16.